current & future outlooks on car-t therapy & bispecific antibodies in follicular lymphoma
Published 1 year ago • 157 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:56
the future of bispecific antibodies in the treatment and management of r/r follicular lymphoma
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
2:38
weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:08
update on mb-106: cd20 car-t therapy for follicular lymphoma
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
0:58
car-t therapy in non-hodgkin lymphoma: current status and future outlooks
-
2:25
the future of car-t for the treatment of lymphoma
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:49
car-t cell approaches in cll: current progress & future directions
-
1:13
the future of car t-cells and bispecific antibodies to treat myeloma
-
2:30
car-t as a new standard of care in lymphoma
-
3:21
practical considerations for car-t therapy in lymphoma
-
1:41
current and emerging indications for car-t therapy in lbcl
-
1:14
the car t-cell strategy vs bispecific antibodies